Finoriq research workspace
Adicet Bio, Inc. (ACET) News
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta. Review ACET recent headlines, source links, and company news on Finoriq.
Company Snapshot
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
- Company
- Adicet Bio, Inc. (ACET)
- Ticker
- ACET
- Market Cap
- $74.7M
- Latest Price
- $7.99
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.